Atsena Therapeutics
Rachel Smith has a strong background in regulatory affairs and research and development. Rachel is currently serving as the Vice President of Regulatory at Atsena Therapeutics since January 2023. Prior to that, they held various roles at StrideBio, Inc, including Vice President of Regulatory Affairs and Translational Development from April 2022 to December 2022, and Vice President of Regulatory Affairs from November 2021 to April 2022.
Before joining StrideBio, Inc, Rachel worked as the President of Ruckdeschel Smith Consulting from July 2018 to December 2021. Rachel also held multiple positions at Capricor Therapeutics, Inc, including Senior Vice President of Research and Development from March 2018 to July 2018, Vice President of Research and Development from October 2012 to March 2018, Director of Research and Development from April 2009 to September 2012, and Senior Scientist from January 2008 to April 2009.
Rachel's earlier experience includes working at Cedars-Sinai as a Research Scientist, Faculty from January 2013 to June 2015, and as a Research Scientist from November 2008 to January 2013.
Rachel Smith earned their Bachelor of Science degree in Biomedical Engineering from Tulane University from 1997 to 2001. Rachel furthered their education at The Johns Hopkins University School of Medicine, where they completed their PhD in Biomedical Engineering from 2001 to 2007.
This person is not in any teams
This person is not in any offices
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. They have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Their additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease.